(CercleFinance.com) – Credit Suisse maintains its Outperformance opinion on the Merck stock and its target price of $126.
‘Merck is preparing to present a series of data on advanced or metastatic lung cancer (NSCLC) from its phase 2 study evaluating MK-2870 as monotherapy in patients refractory to standard therapies’, notes the analyst.
Given the importance of unmet needs in the field of CPNPC 2L+, ‘Merck has the opportunity to conquer new market shares’, continues the broker.
However, Credit Suisse does not include the MK-2870 and ADCs from the Kelun collaboration in its forecast, but sees, ‘this initial data set as the first step towards de-risking its new ADC pipeline’.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
